报告
已发布: 22 六月 2018

Wellcome Trust

Not enough new antibiotics are in development to guarantee that we can continue to treat infections. Current market conditions will not incentivise the investment necessary to restock the antibiotic pipeline, and “push” funding that directly supports early-stage R&D is insufficient to create a functioning market for the future.

This briefing outlines why pull incentives are necessary; some of the key principles they need to fulfill; and next steps towards implementing or piloting a pull incentive.

Not enough new antibiotics are in development to guarantee that we can continue to treat infections. Current market conditions will not incentivise the investment necessary to restock the antibiotic pipeline, and “push” funding that directly supports early-stage R&D is insufficient to create a functioning market for the future.

This briefing outlines why pull incentives are necessary; some of the key principles they need to fulfill; and next steps towards implementing or piloting a pull incentive.

许可和重新发布

世界经济论坛报告可能会根据我们的使用条款重新发布。

订阅更新

每周更新全球议程内容

© 2022 World Economic Forum

隐私政策和服务条款

Join the Forum